Cephalon — Proxy Contest (April 2011)
33 slides from Cephalon's proxy contest presentation, Apr 7, 2011
Slide 1: Cephalon
(e), Cephalon
Slide 2: Participants in the solicitation of consent revocations
2 2 Cephalon, Inc. (the "Company"), its directors and certain of its officers and employees may be deemed to be participants in the solicitation of consent revocations from stockholders in connection with a consent solicitation by Valeant Pharmaceuticals International, Inc. ("Valeant") to replace th
Slide 3: We urge investors to read the consent revocation statement
3 3 WE URGE INVESTORS TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY SUPPLEMENTS THERETO), THE COMPANY'S SOLICITATION/RECOMMENDATION STATEMENT REGARDING ANY TENDER OFFER THAT MAY BE COMMENCED BY VALEANT, AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECO
Slide 4: Safe Harbor Statement
4 Safe Harbor Statement This presentation contains forward-looking statements that involve risks and uncertainties. These statements may concern, among other things, our business strategy and market opportunities, the development of pharmaceutical products, and future financial and operating results
Slide 5: Situation Overview & Strategy
5 Situation Overview & Strategy
Slide 6: Situation Overview
6 6 Situation Overview § On March 3, the Valeant and Cephalon CEOs had an introductory meeting. No proposal of any kind was made § On March 18, Cephalon received a letter from Valeant with a $73 per share proposal for 100% of Cephalon shares - Valeant requested a response by April 1 § On March 25, o
Slide 7: Valeant's Strategy: "Speed" at the Expense of Process Harms Cephalon Shareholders
7 7 Valeant’s Strategy: “Speed” at the Expense of Process Harms Cephalon Shareholders § Valeant is attempting to quickly force a takeover that is not in the best interest of Cephalon’s shareholders “We maximize speed and believe “deal process” creates distractions.” - Valeant’s Transaction Operating
Slide 8: Cephalon's Approach
8 8 Cephalon’s Approach § We have built a leading, global biopharmaceutical platform that is diversified across both products and geographies § Over the past two years, Cephalon has created one of the broadest late-stage pipelines in the industry § This pipeline has significant near- to mid-term com
Slide 9: Our Assessment of Valeant's Proposal
9 Our Assessment of Valeant’s Proposal
Slide 10: Valeant's $73 Proposal is Inadequate
10 10 Valeant’s $73 Proposal is Inadequate § 30-day average of $56.74 is near our 52-week low and not the appropriate reference point § Premium is significantly below precedent life sciences benchmarks § It is based on a “worst-case” scenario § It ascribes little-to-no value to Cephalon’s late-stage
Slide 11: Valeant's $73 Proposal Represents Virtually NO Premium to 52-Week High
11 11 Valeant’s $73 Proposal Represents Virtually NO Premium to 52-Week High Premium to 30 days prior Note: 2006-2011 YTD pharmaceutical, specialty pharmaceutical and biotechnology precedent transactions with US-listed target, enterprise value > $500 million, > 50% cash consideration (n = 34). Exclu
Slide 12: Valeant Proposal Based on Worst-Case Scenario
12 12 Valeant Proposal Based on Worst-Case Scenario § Valeant’s $73 proposal is based on a worst-case scenario “We took the absolute worst case as one of our analyses....we assumed the worst, the worst in terms of IP, the worst in terms of sort of everything, everything we could think of...if the wo
Slide 13: Valeant's Proposal Ascribes Little-to-No Value to Late-Stage Pipeline
13 13 Valeant’s Proposal Ascribes Little-to-No Value to Cephalon’s Late-Stage Pipeline § Valeant does not believe in R&D and ascribes little-to- no value to Cephalon’s late-stage pipeline “Do not bet on science, bet on management.” - Valeant Strategy, Investor Presentation, March 30, 2011 § Cephalon
Slide 14: Cephalon's Proven Track Record
14 Cephalon’s Proven Track Record
Slide 15: A History Of Strong Sales Growth
15 15 A History Of Strong Sales Growth *2011 estimates depict the midpoint of guidance ranges provided in press release issued 2/10/11. $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 Oncology Other Pain CNS Sales CAGR: 30%
Slide 16: Focus on Cash Flow Generation
16 16 Focus on Cash Flow Generation * Excludes $425 million paid in 2008 in association with the settlement agreement with the U.S. Attorney’s Office that was considered a reduction in net cash provided by operating activities. ** Excludes $100 million paid to Angioblast for a license associated wit
Slide 17: Ability to Identify, Develop and Commercialize Assets
17 Ability to Identify, Develop and Commercialize Assets Asset Acquisition Cost Cumulative Sales Through 4Q 2010 Cephalon Launch Year Lafon (PROVIGIL/NUVIGIL) $448 $7,587 1998 GABITRIL $110 $586 2000 Anesta (ACTIQ) $357 $2,865 2000 TRISENOX $70 $129 2005 CIMA (FENTORA & other) $483 $872 2006 Zeneus
Slide 18: Our Pipeline Presents Substantial Value
18 Our Pipeline Presents Substantial Value Targeted Launch Product Indication Current Status Estimated Peak Sales 2012 Tamper Deterrent Hydrocodone Chronic pain Phase III $500 2012 TREANDA 1 st line iNHL Phase III $600 2012 OMAPRO* 3 rd line CML Preparing NDA $150 2013 NUVIGIL Bipolar depression Pha
Slide 19: Key Attributes Of Cephalon's Recent Acquisitions
19 Key Attributes Of Cephalon’s Recent Acquisitions 1) Solid, enduring intellectual property § Composition of matter patents § 12 years biologics exclusivity 2) Unique products that payers will embrace § Meet major unmet medical need § 1 st or 2 nd in class products § Unique compounds, not reformula
Slide 20: Summary
20 20 Summary § 30-day average of $56.74 is near our 52-week low and not the appropriate reference point § Premium is significantly below precedent life sciences benchmarks § It is based on a “worst-case” scenario § It ascribes little-to-no value to Cephalon’s late-stage pipeline § It does not refle
Slide 21: Supplemental Information
21 Supplemental Information
Slide 22: Cephalon Overview
22 22 Cephalon Overview § Global biopharmaceutical company with well- diversified product and geographic mix (170 products sold in more than 100 countries) § Offering of branded, branded generic and generic products § Branded portfolio focused on wakefulness and neurological disorders, oncology, pai
Slide 23: Diversified Product Portfolio
23 23 Diversified Product Portfolio CIMA Products European Proprietary Products U.S. Proprietary Products
Slide 24: Cephalon's Growing Global Presence
24 24 Cephalon’s Growing Global Presence Sales in more than 100 countries and over 170 products sold
Slide 25: Mesenchymal Precursor Cell (MPC) Revascor
25 Mesenchymal Precursor Cell (MPC) Revascor Description Data Potential Timeline § Produce cytokines and/or growth factors that induce endogenous tissue repair or cell proliferation § Data indicated that MPC treatment reduced MACE, hospitalization and mortality in CHF § Animal studies demonstrated i
Slide 26: CINQUIL
26 CINQUIL™ Description Data Potential Timeline § Humanized mAb against IL-5 § Designed to reduce airway eosinophils § Phase IIb study results demonstrated: § Reduction of sputum eosinophil counts § Improvements on the asthma control questionnaire, FEV1, FVC, and clinical asthma exacerbations § ~30%
Slide 27: LUPUZOR
27 LUPUZOR™ Description Data Potential Timeline § Immune modulator believed to: § Reduce auto-antigen processing in antigen-presenting B cells § A decrease in the priming and signaling of auto-reactive T-cells § Phase IIb study results showed a clinically significant improvement in the intent to tre
Slide 28: OMAPRO
28 OMAPRO™ Description Data Potential Timeline § First-in-class cetaxine (small molecule) § Induces apoptosis by inhibition of protein synthesis § Promising data for the treatment of chronic myeloid leukemia in patients who failed or are intolerant to Gleevec® and one other tyrosine kinase inhibitor
Slide 29: Obatoclax
29 Obatoclax Description Data Potential Timeline § Pan Bcl-2 inhibitor with preclinical and clinical activity § Observed as both a single agent and in combination with standard therapies for various cancers including extensive stage small cell lung cancer (ES-SCLC) § Completed first line, phase IIb
Slide 30: Tamper Deterrent Hydrocodone
30 Tamper Deterrent Hydrocodone Description Data Potential Timeline § Polymer-coated particles compressed into twice-daily, acetaminophen-free tablets § Formulation has demonstrated a resistance to immediate release of drug when crushed or mixed with alcohol § 26 million+ long-acting opioid prescrip
Slide 31: CEP-37247 (Domain Antibody Anti-TNF)
31 CEP-37247 (Domain Antibody Anti-TNF) Description Data Potential Timeline § Domain antibody anti-TNF for epidural injection to treat sciatica § TNF is a key cytokine mediator in the pathophysiology of sciatica § Two small studies with etanercept have demonstrated proof of concept § ~14% of all chr
Slide 32: Larazotide Acetate
32 Larazotide Acetate Description Data Potential Timeline § Tight junction modulator § Early research suggests larazotide acetate may help keep the tight junctions closed when ingested prior to a meal, thus reducing the inflammatory process in response to gluten § Demonstrated a signal of efficacy i
Slide 33: Primary Patents Covering Potential Launches
33 Primary Patents Covering Potential Launches Product Patent Type Expiration* Market Exclusivity TD Hydrocodone Formulation** 2027 TREANDA Composition of matter on polymorph** 2015 / 2029 NCE exclusivity to 2013 plus 6 months pediatric extension plus time of ANDA OMAPRO Method of treatment 2023 NUV